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C BY-NC-Abstract The objective of this study is to obtain a data on the prevalence of bisphosphonate-asso-
ciated osteonecrosis of the jaws (ONJ) among patients who received dental treatment in Riyadh.
The study was conducted in ﬁve hospitals in Riyadh area. All subjects were interviewed to collect
data regarding their medical history, bisphosphonates usage, dental history, and possible complica-
tions after dental treatment. A total of 88 subjects under bisphosphonates therapy were interviewed,
25% were males and 75% were females. Bisphosphonates were taken orally by 89.7% of the sub-
jects while 10.2% received bisphosphonate intravenously. All the subjects have had dental treat-
ment after the beginning of bisphosphonate therapy. 79.5% of those patients had dental
extraction, 13.6% root canal treatment, 4.5% oral surgery, and 4.5% received dental implants.
No complications were reported after dental treatment.
In the present study, patients with bisphosphonates therapy did not develop complication after
dental treatment. However, it is recommended that patients receiving bisphosphonate therapy
should be treated with precaution. Dental awareness programs should be provided to the physicians
prescribing bisphosphonates to their patients.
ª 2011 King Saud University. Production and hosting by Elsevier B.V..com
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Bisphosphonate therapy is one of the most important anti-
resorptive agents used in the treatment of variety of diseases
such as: osteoporosis, metabolic bone diseases, metastatic dis-
eases to the bone, hypercalcemia, Paget’s disease and multiple
myeloma (Estilo et al., 2008; Marx et al., 2005; Seehra et al.,
2009; Walter et al., 2007).
Bisphosphonates are group of medicine available in different
format such as, alendronate (Fosamax), pamidronate (Are-
dia), risedronate (Actonel), and zoledronic acid (Zometa).
Bisphosphonates are commonly used in tablet form to treat
osteoporosis in post-menopausal women (Grbic et al., 2008;
Holder and Kerley, 2008; Wells et al., 2008). Stronger forms
Table 1 Medical status of the study sample.
Medical condition/risk factor Percentage (%)
Bone diseases 86
Hypertension 47.7
Diabetes 36.4
Rheumatological diseases 34
Blood diseases 9.1
Cancer 9
Smoking 4.5
30 H.A. Alzomangiven orally or intravenously (iv) are used in the management
of advanced cancer cases when the cancer cells have metasta-
sized to the bone causing pain and possible bone fractures
(Smith et al., 2009; Wadhwa et al., 2010; Walter et al., 2009).
Bisphosphonates act at the cell level by targeting osteoclasts
and disrupting their function in several ways: They inhibit
osteoclast recruitment, reduce osteoclast lifespan, and inhibit
bone surface activity of these cells which will lead to reduction
in bone resorption (Hokugo et al., 2010; Marx et al., 2005).
When bisphosphonate absorbed form the gastrointestinal tract
around 50% of the dose binds to bone. The half-life of bis-
phosphonates in bone is very long, ranging from 1 to 10 years,
depending largely on the rate of bone turnover.
An association between bisphosphonates and a serious bone
disease called osteonecrosis of the jaw (ONJ) has been reported
in several articles (Dimitrakopoulos et al., 2006; Fugazzotto
and Lightfoot, 2006; Hong et al., 2010; Kicken et al., 2007;Lan-
ger, 2006). ONJ is a condition in which the bone tissue in the jaw
fails to heal after minor or major oral surgeries, such as tooth
extraction, causing the bone to be exposed. This exposure can
eventually lead to a serious infection and may even lead to bone
fracture (Arribas-Garcia et al., 2009; Basu and Reid, 2007).
Food and Drug Administration (FDA) in the United States
raised a warning to the health care professionals on September
24, 2004 regarding the potential risk of performing dental
extraction or other oral surgery in patients receiving bis-
phosphonate therapy. Most of the reported ONJ were associ-
ated with patients when bisphosphonates were given
intravenously or for longer periods of time (Vahtsevanos et
al., 2009; Lodi et al., 2010; Statz et al., 2007).
In addition, some classes of bisphosphonates have shown
higher tendency to develop ONJ (Marx et al., 2005) reported
that ONJ cases were associated with pamidronate and zoled-
ronic acid compared to the other format of bisphosphonates.
The aim of the study is to obtain data on the prevalence of
bisphosphonate-associated osteonecrosis of the jaws in a se-
lected Saudi population.2. Materials and methods
The present study was conducted among selected sample of
Saudi patients under bisphosphonate therapy attending outpa-
tient and inpatients clinics in ﬁve major hospitals in Riyadh.
These hospitals include King Khalid University Hospital,
Security Forces Hospital, Military Hospital, King Abdulaziz
University Hospital and Sultan Bin Abdulaziz Humanitarian
City. After taking the consent of the patient, an interview
was performed to collect patient information, medical history,
bisphosphonates usage, and dental history. During the inter-
view the patients’ medical records were checked to obtain the
required information.
Ethical approval was obtained from the Ethical Committee
of the College of Dentistry Research Center. Data was entered
and analyzed using Statistical Package for Social Science
(SPSS version 13).Figure 1 Percentage of the performed dental treatment.3. Results
A total of 88 patients, 22 males (25%) and 66 females (75%),
were interviewed. The age of the subjects ranged between 30
and 80 years with an average age of 58 years.Majority of patients have bone diseases, 86%. The other
patients’ medical conditions are summarized in Table 1.
All subjects were using bisphosphonates for a period ranged
from 1 year up to 9 years with a mean duration of 2.6 years.
Bisphosphonates were taken orally by 79 patients (89.7%).
The medication was taken orally as alendronate with a dose
of 70 mg/week. Whereas, 9 patients (10.2%) received bis-
phosphonate intravenously as pamidronate with a dose of
90 mg over a variable period of time.
All the patients have had dental treatment after the begin-
ning of bisphosphonate therapy. Majority of them visited their
dentists within 1–2 years.
During the reported dental visits 79.5% of those patients
had dental extraction, 13.6 had Root canal treatment, 4.5%
had oral surgery, and 4.5% received dental implants (Fig. 1).
No complications after dental treatments were reported by
the subjects.
All subjects reported that they were not informed about any
possible complication that may arise after dental treatments by
dentists or by their treating physicians.
4. Discussion
An association between bisphosphonates and osteonecrosis of
the jaw (ONJ) has been reported in several reports. In the pres-
ent study, none of the subjects who received bisphosphonates
therapy developed (ONJ) after dental treatment. The ﬁnding
Prevalence of jaw osteonecrosis among patients receiving bisphosphonates in Riyadh 31of this study is in consistent with other study which reported no
complication after dental treatment in patients receiving bis-
phosphonate therapy (Malmgren et al., 2008) In other studies,
no complications were reported after dental implant surgeries
(Fugazzotto et al., 2007; Grant et al., 2008; Jeffcoat, 2006; Tor-
res et al., 2009). On the other hand, Lo et al. (2010) reported a
prevalence of 0.1% of ONJ among a survey on 8572 subjects
using oral bisphosphonate therapy. In addition, Sedghizadeh
et al. (2009) reported 4% occurrence of ONJ in therapy in
which most of those patients were old with an average age of
73 years old. Other risk factors were also associated with in-
creased incidence of ONJ such as type II diabetes, steroid ther-
apy and chemotherapy patients under bisphosphonates.
Osteonecrosis is caused by impaired blood supply to the
bone, but it is not always clear what may cause this impair-
ment. Osteonecrosis often occurs in people with certain risk
factors and medical conditions. However, it also affects people
with no health problems and for unknown reasons (Migliorati
et al., 2005). Majority of the reported cases of bisphosphonate
induced ONJ were found in patients older than 60 years of age
(Hong et al., 2010; Kicken et al., 2007). Additionally, the
majority of the ONJ cases were associated with intravenous
bisphosphonates, or with long usage of bisphosphonates with
other treatment modalities such as: chemotherapy, steroids in-
take, or radiotherapy (Vahtsevanos et al., 2009; Lodi et al.,
2010; Statz et al., 2007).
Generally, Patients receiving oral bisphosphonates like
alendronate have lower risk than patients with high potent bis-
phosphonates for cancer treatment pamidronate and zoledron-
ic acid. (Wessel et al., 2008) reported that cancer patients who
had received zoledronate exhibited a signiﬁcant 30-fold in-
crease in their risk to develop ONJ. Moreover, a long term
use of oral bisphosphonates (fosamax) is considered also as
potential risk factor.
In literature there are conﬂicting conclusions regarding the
association between bisphosphonate therapy and ONJ which
indicate that there are other potential risk factors to be studied
to understand the nature of bisphosphonate induced ONJ.
5. Conclusions
The results of the present study showed no complication after
dental treatment among the assessed patients who had history
of bisphosphonate therapy. However, until more information
is revealed, it is recommended that patients receiving bis-
phosphonate therapy should be treated with precaution. Addi-
tionally, patients should be referred to dentists for evaluation
and comprehensive treatment prior to the start of bisphospho-
nate therapy.
Dental awareness programs should be provided to the physi-
cians prescribing bisphosphonates for their patients to elaborate
on the risk of developingONJafter bisphosphonates treatments.
Finally, further studies should be conducted to assess the
other potential risk factors which might lead to bisphospho-
nate induced ONJ.Acknowledgments
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